Data and code availability
All data supporting this study are available within the main article and supplemental information. This study did not generate any datasets or original code.
The long-lasting COVID-19 pandemic and increasing SARS-CoV-2 variants demand effective therapeutic strategies. Herein, we have engineered unique unnatural amino acids into proteins and developed covalent nanobodies capable of irreversibly binding with the viral spike protein. These covalent nanobodies are able to neutralize both SARS-CoV-2 and its different variants with drastic higher potency than traditional nanobodies, affording a potential prophylactic and medication for COVID-19. In addition, our strategy could provide an original general route to developing effective therapeutics for various other viral infections, such as influenza, hepatitis, AIDS, and anthrax.
All data supporting this study are available within the main article and supplemental information. This study did not generate any datasets or original code.